Arterial hypertension and gout: the current state of the problem (literature review).

A. P. Kuzmina, O. N. Lazarenko

Abstract


An important aspect of the family doctor's work is the management of patients with comorbid pathology. Pathogenetic mechanisms of interrelation, as well as the bi-directionality of the association of arterial hypertension and gout are actively studied. By data analysis of literature, in many developed countries of the world there are shortcomings in the management of patients with gout at the primary stage. There is a need to improve the quality of management and prescription of combinations of basic therapy drugs for the treatment of patients with hypertension in combination with gout at the primary stage.

 


Keywords


arterial hypertension; gout; antihypertensive drugs; urat-lowering therapy

Full Text:

PDF

References


Antyuk ZhO. [State of lipid metabolism in patients with gout]. Vіsnik SumDU. 2010;2:52-55. Uk­rainian.

Ivanova KV. [Rational treatment of arterial hypertension in patients with gout and asymptomatic hyperuricemia in a polyclinic. Extended abstract of candidate’s thesis].Orenburg; 2013. Russian.

Il'ina AE, Barskova VG, Nasonov EL. [Gout, hyperuricemia and cardiovascular risk]. Nauchno-prak­ticheskaya revmatologiya. 2009;1:56-62. Russian.

Tsurko VV, Egorov IV, Eliseeva MV. [Gout: cardiovascular pathology and antihypertensive therapy]. Klinicheskaya gerontologiya. 2013;19(1-2):3-7. Russian.

Yakimenko OO, ZakatovaLV, Antіpova NM. [Dynamics of the structure of rheumatic diseases for 30 years (1983-2013) inOdessa]. Ukraїns'kiy revma­tologіchniy zhurnal. 2014;57(3):94-95. Ukrainian.

McAdams-DeMarco MA, Maynard JW, Baer AN, et al. Hypertension and the risk of incident gout in a population-based study: the atherosclerosis risk in com­munities cohort. J Clin Hypertens (Greenwich). 2012;14(10):675-9.

Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(6):435-42.

Kok VC, Horng JT, Chang WS, et al. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS One. 2014;9(6):e99102. doi: 10.1371/journal.pone.0099102.

Hsu PF, Chuang SY, Cheng HM, et al. As­sociations of serum uric acid levels with arterial wave reflections and central systolic blood pressure. Int J Cardiol. 2013;168(3):2057-63.

Choi HK, Soriano LC, Zhang Y, et al. Anti­hypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190.

Krishnan SM, Sobey CG, Latz E, et al. IL-1β and IL-18: inflammatory markers or mediators of hyper­tension? Br J Pharmacol. 2014;171(24):5589-602.

Jeyaruban A, Larkins S, Soden M. Management of gout in general practice – a systematic review. Clin Rheumatol. 2015;34(1):9-16.

Juraschek SP, Kovell LC, Miller ER, et al. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. PLoS One. 2013;8(2):e56546. doi: 10.1371/journal.pone.0056546.

Pillinger MH, Goldfarb DS, Keenan RT. Gout and Its Comorbidities. Bull NYU Hospit J Dis. 2010;68(3):199-203.

Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Popu­lation. J Rheumatol. 2015;42(9):1702-7.

Rodriguez-Iturbe B, Franco M, Tapia E, et al. Re­nal inflammation, autoimmunity and salt-sensitive hy­pertension. Clin Exp Pharmacol Physiol. 2012;39:96-103.

Ruilope LM, Kirwan BA, de Brouwer S, et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal the­rapeutic system) and relation to outcome. J Hypertens. 2007;25(8):1711-8.

Terrill M, Riordan J. A survey of the assessment and management of gout in general practitioners and medical officers within the IllawarraNetwork,Australia. Int J Rheum Dis. 2017;20(8):990-5.

Turak O, Ozcan F, Tok D, еt al. Serum uric acid, inflammation, and nondipping circadian pattern in es­sential hypertension. J Clin Hypertens (Greenwich). 2013;15(1):7-13.

Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of out. Annals of the Rheumatic Diseases. 2016. Available from: http://ard.bmj.com/con­tent/early/2016/07/25/annrheumdis-2016-209707.full.pdf+html.

Yu FN, Shi YX, Cheng HY, et al. An ob­servational study on the relationship between serum uric acid and hypertension in a Northern Chinese population aged 45 to 59 years. Medicine (Baltimore). 2017;96(17).e6773. doi: 10.1097/MD.0000000000006773.


GOST Style Citations


  1. Антюк Ж.О. Стан ліпідного обміну у пацієнтів з подагрою / Ж.О. Антюк // Вісник СумДУ. – 2010. – № 2. – С. 52-55.
  2. Иванова К.В. Рациональное лечение арте­риальной гипертонии у больных подагрой и бес­симптомной гиперурикемией в условиях поликли­ники : автореф. дисс. на соискание ученой степени канд. мед. наук : спец. 14.01.22 «Ревматология» / К.В. Ива­нова. – Оренбург, 2013. –31 с.
  3. Ильина А.Е. Подагра, гиперурикемия и кар­диоваскулярный риск / А.Е. Ильина, В.Г. Барскова, Е.Л. Насонов // Науч.-практ. ревматология. – 2009. – № 1. – С. 56-62.
  4. Цурко В.В. Подагра: сердечно-сосудистая па­то­логия и антигипертензивная терапия / В.В. Цурко, И.В. Егоров, М.В. Елисеева // Клинич. геронтология. – 2013. – № 19 (1-2). – С. 3-7.
  5. Якименко О.О. Динаміка структури ревма­тичних захворювань за 30 років (1983–2013) у Одесі / О.О. Якименко, Л.В. Закатова, Н.М. Антіпова // Укр. ревматол. журнал. – 2014. – Т. 57, № 3. – С. 94-95.
  6. McAdams-DeMarco M.A. Hypertension and the risk of incident gout in a population-based study: the atherosclerosis risk in communities cohort / M.A. McAdams-DeMarco, J.W. Maynard, A.N. Baer [et al.] // J. Clin. Hypertens (Greenwich). – 2012. – Vol. 14, N 10. – P. 675-679.
  7. Agarwal V. Effect of allopurinol on blood pres­sure: a systematic review and meta-analysis / V. Agarwal, N. Hans, F.H. Messerli // J. Clin. Hypertens (Greenwich). – 2013. – Vol. 15, N 6. – P. 435-442.
  8. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study / V.C. Kok, J.T. Horng, W.S. Chang [et al.] // PLoS One. 2014. – Vol. 9, N 6. – e99102. doi: 10.1371/journal.pone.0099102.
  9. Associations of serum uric acid levels with arterial wave reflections and central systolic blood pres­sure / P.F. Hsu, S.Y. Chuang, H.M. Cheng [et al.] // Int. J. Cardiol. – 2013. – Vol. 168, N 3. – P. 2057-2063.
  10. Choi H.K. Antihypertensive drugs and risk of incident gout among patients with hypertension: popu­lation based case-control study / H.K. Choi, L.C. Soriano, Y. Zhang [et al.] // BMJ. – 2012. – Vol. 344. – d8190.
  11. IL-1β and IL-18: inflammatory markers or media­tors of hypertension? / S.M. Krishnan, C.G. Sobey, E. Latz [et al.] // Br. J. Pharmacol. – 2014. – Vol. 171, N 24. – P. 5589-5602.
  12. Jeyaruban A. Management of gout in general practice – a systematic review / A. Jeyaruban, S. Larkins, M. Soden // Clin. Rheumatol. – 2015. – Vol. 34, N 1. – P. 9-16.
  13. Juraschek S.P. Dose-response association of un­controlled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout /  S.P. Juraschek, L.C. Kovell, E.R. Miller // PLoS One. 2013. – Vol. 8, N 2. – e56546. doi: 10.1371/journal.pone.0056546.
  14. Pillinger M.H. Gout and Its Comorbidities / M.H. Pillinger, D.S. Goldfarb, R.T. Keenan. // Bull NYU Hospit. J. Dis. – 2010. – Vol. 68, N 3. – P. 199-203.
  15. Robinson P.C. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population / P.C. Robinson, W.J. Taylor, N. Dalbeth // J. Rheumatol. – 2015. – Vol. 42, N 9. – P. 1702-1707.
  16. Rodriguez-Iturbe B. Renal inflammation, autoim­munity and salt-sensitive hypertension / B. Rodriguez-Iturbe, M. Franco,E. Tapia// Clin. Exp. Pharmacol. Physiol. – 2012. – Vol. 39. – P. 96-103.
  17. Ruilope L.M. Uric acid and other renal function parameters in patients with stable angina pectoris par­ticipating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome / L.M. Ruilope, B.A. Kirwan, S. de Brouwer // J. Hypertens. – 2007. – Vol. 25, N 8. – P. 1711-1718.
  18. Terrill M. A survey of the assessment and mana­gement of gout in general practitioners and medical officers within the Illawarra Network, Australia / M. Terrill, J. Riordan // Int. J. Rheum. Dis. – 2017. – Vol. 20, N 8. – P. 990-995.
  19. Turak O. Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension / O. Turak, F. Ozcan, D. Tok // J. Clin. Hypertens (Greenwich). – 2013. – Vol. 15, N 1. – P. 7-13.
  20. 2016 updated EULAR evidence-based recom­mendations for the management of gout / P. Richette, M. Doherty, E. Pascual [et al.] // Ann. Rheumatic Diseases. – 2016. Available from: http://ard.bmj.com/content/early/­2016/07/25/annrheumdis-2016-209707.full.pdf+html.
  21. Yu F.N. An observational study on the rela­tionship between serum uric acid and hypertension in a Northern Chinese population aged 45 to 59 years / F.N. Yu, Y.X. Shi, H.Y. Cheng // Medicine (Bal­timore). – 2017. – Vol. 96, N 17. – e6773. doi: 10.1097/MD.0000000000006773.




DOI: https://doi.org/10.26641/2307-0404.2017.4.117662

Refbacks

  • There are currently no refbacks.